Gianluca Gaïdano - Concepedia

Author

Gianluca Gaïdano

Università degli Studi del Piemonte Orientale “Amedeo Avogadro”ORCID

Also Known As

A. Lopez Guillermo, Andrea Patriarca, C ZUCCONI, D. Rossi, Davide Rossi, Diane C. Louie, FOA, Roberto, Federica Grosso, Francesca D'Avanzo, G GAIDANO

1.5K

Publications

49K

Citations

113

H-Index

193

Concepts

All Affiliations

Università degli Studi del Piemonte Orientale “Amedeo Avogadro”Istituti di Ricovero e Cura a Carattere Scientifico University of Turin Centro di Riferimento Oncologico Institute of Oncology Research

About

Gianluca Gaïdano is an author at Università degli Studi del Piemonte Orientale “Amedeo Avogadro” specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	64	189	15.8K
2	Health Sciences	27	35	3K
3	Engineering	5	5	390
4	Public Health	3	3	78
5	Natural Sciences	2	2	281

Gianluca Gaïdano

487

Publications

41.1K

Citations

106

H-Index

Page 1

	Year	Citations
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, New England Journal of Medicine	2015	1.5K
Analysis of the coding genome of diffuse large B-cell lymphoma Laura Pasqualucci, Giulia Fabbri, Jing Ma, Nature Genetics Hematological MalignancyLymphoid NeoplasiaNext-generation SequencingPathologyMolecular Genetics	2011	957
Inactivating mutations of acetyltransferase genes in B-cell lymphoma Laura Pasqualucci, David Dominguez-Sola, Annalisa Chiarenza, Nature B-cell LymphomaLymphoid NeoplasiaPathologyAdult T-cell Leukemia-lymphomaMedicine	2011	919
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Gianluca Gaïdano, Paola Ballerini, Jerry Z. Gong, Proceedings of the National Academy of Sciences Chronic Lymphocytic LeukemiaMixed-phenotype Acute LeukemiaImmunologyPathologyP53 Loss/inactivation	1991	896
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo, The Lancet Oncology Hematological MalignancyOncologyDexamethasone Versus BortezomibHematologyMyeloid Neoplasia	2015	834
Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation Giulia Fabbri, Silvia Rasi, Davide Rossi, The Journal of Experimental Medicine	2011	602
Genetics of Follicular Lymphoma Transformation Laura Pasqualucci, Hossein Khiabanian, Marco Fangazio, Cell Reports	2014	571
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study Gilles Salles, Johannes Duell, Eva González‐Barca, The Lancet Oncology Lymphoid NeoplasiaMedicineMalignant Blood DisorderImmunologyPathology	2020	504
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma David M. Kurtz, Florian Scherer, Michael C. Jin, Journal of Clinical Oncology	2018	472
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia Davide Rossi, Silvia Rasi, Valeria Spina, Blood	2012	454

Page 1